BUYER WORKSHEET
How to select a CRO for a Phase II/III trial: RFI questions
Ask every shortlisted CRO the same six questions so answers—especially pricing, named leads, and US sites—can be compared side by side.
- Indication & phase references: Which studies match this exact indication, phase, and patient population? Share sponsor references and the CRO's exact functional role.
- Named study team: Who will serve as medical monitor, CTM, lead DM, and lead biostatistician—what is their relevant experience and allocated FTE?
- US sites & recruitment plan: Which US investigators and sites are active in this indication, and how do you avoid competing-trial bottlenecks?
- Delivery model & handoffs: Are you proposing full-service, FSP, or hybrid? Which labs, EDC, or in-home/DCT vendors are owned vs. subcontracted?
- Schedule assumptions: What regulatory, startup, IRB, and database-lock assumptions drive the timeline?
- Price, pass-throughs & change orders: What is fixed vs. time-and-materials, which investigator/pass-through costs are excluded, and what triggers a change order?
Read how these questions relate to the reviewed evidence · ← Back to overview
Turn a continuity promise into a named-team commitment
A company’s delivery model cannot tell you who will work on your study next quarter.
Medpace · published approach
Medpace says one team stays with a project from early discussions through completion.
This is a vendor promise, not a named-team commitment or measured retention result. Ask the proposal to name roles, allocation and substitution terms. Source & date